Vestergaard Kvist, A.; Faruque, J.; Vallejo-Yagüe, E.; Weiler, S.; Winter, E.M.; Burden, A.M.
Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J. Clin. Med. 2021, 10, 1660.
https://doi.org/10.3390/jcm10081660
AMA Style
Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, Weiler S, Winter EM, Burden AM.
Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Journal of Clinical Medicine. 2021; 10(8):1660.
https://doi.org/10.3390/jcm10081660
Chicago/Turabian Style
Vestergaard Kvist, Annika, Junaid Faruque, Enriqueta Vallejo-Yagüe, Stefan Weiler, Elizabeth M. Winter, and Andrea M. Burden.
2021. "Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)" Journal of Clinical Medicine 10, no. 8: 1660.
https://doi.org/10.3390/jcm10081660
APA Style
Vestergaard Kvist, A., Faruque, J., Vallejo-Yagüe, E., Weiler, S., Winter, E. M., & Burden, A. M.
(2021). Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Journal of Clinical Medicine, 10(8), 1660.
https://doi.org/10.3390/jcm10081660